Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

COURTNEY CRAWFORD

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1265546170
CMS profile
371490
Location
BURLESON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$38,535.99

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

COURTNEY CRAWFORD

NPI 1265546170 · CMS profile ID 371490

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

BURLESON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265546170?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
COURTNEY CRAWFORD, NPI 1265546170, CMS profile ID 371490. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265546170?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). COURTNEY CRAWFORD, NPI 1265546170, CMS profile ID 371490. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265546170?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
COURTNEY CRAWFORD, NPI 1265546170, CMS profile ID 371490, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265546170?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $38,535.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Apellis Pharmaceuticals, Inc. $180.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154018906 CMS
Apellis Pharmaceuticals, Inc. $180.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154018908 CMS
Regeneron Healthcare Solutions, Inc. $529.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114030929 CMS
Apellis Pharmaceuticals, Inc. $1,500.0001/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154018900 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,578.46 15
PY2020 $49.36 2
PY2021 $12,671.22 29
PY2022 $83,413.25 39
PY2023 $166,125.83 76
PY2024 $38,535.99 54
PY2025 $35,744.16 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $647,931.28 88
PY2024 Principal investigator $10,500.00 2
PY2023 Principal investigator $144,310.05 57
PY2022 Principal investigator $600.00 1
PY2021 Principal investigator $39,381.81 2
PY2020 Principal investigator $13,127.05 1
PY2019 Principal investigator $5,069.85 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $63,671.70 12/29/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239785
Principal investigator 1 Ocular Therapeutix, Inc. $23,378.40 12/24/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239781
Principal investigator 1 Ocular Therapeutix, Inc. $3,389.40 12/24/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,469.31 12/24/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $258.00 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,127.22 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,080.06 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,152.43 12/19/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278614
Principal investigator 1 Ocular Therapeutix, Inc. $5,703.11 12/05/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239777
Principal investigator 1 Ocular Therapeutix, Inc. $2,475.00 12/05/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239779
Principal investigator 1 ABBVIE INC. $22,880.00 12/04/2025 Non-covered Recipient Entity
COURTNEY CRAWFORD MD
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202528538
Principal investigator 1 ABBVIE INC. $1,313.25 12/01/2025 Non-covered Recipient Entity
STAR VISION RESEARCH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202526218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,152.43 11/27/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184265941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,127.22 11/27/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184265943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,080.06 11/27/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184265945
Principal investigator 1 Ocular Therapeutix, Inc. $3,389.40 11/26/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239775
Principal investigator 1 Ocular Therapeutix, Inc. $23,576.40 11/21/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239773
Principal investigator 1 ABBVIE INC. $1,976.00 11/19/2025 Non-covered Recipient Entity
STAR VISION RESEARCH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202524706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184260649
Principal investigator 1 Ocular Therapeutix, Inc. $75,001.50 10/29/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239767
Principal investigator 1 Ocular Therapeutix, Inc. $3,389.40 10/29/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239769
Principal investigator 1 Ocular Therapeutix, Inc. $47,750.40 10/29/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239771
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/16/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239787
Principal investigator 1 Ocular Therapeutix, Inc. $3,007.46 10/10/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239765
Principal investigator 1 Ocular Therapeutix, Inc. $4,780.80 10/08/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184248158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184248160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184248162
Principal investigator 1 Ocular Therapeutix, Inc. $825.00 10/01/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239761
Principal investigator 1 ABBVIE INC. $1,380.00 09/09/2025 Non-covered Recipient Entity
STAR VISION RESEARCH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202510356
Principal investigator 1 Ocular Therapeutix, Inc. $2,704.73 09/03/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239753
Principal investigator 1 Ocular Therapeutix, Inc. $5,544.73 09/03/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239755
Principal investigator 1 Ocular Therapeutix, Inc. $12,322.00 09/03/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239757
Principal investigator 1 Ocular Therapeutix, Inc. $8,152.18 09/03/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239759
Principal investigator 1 ABBVIE INC. $26,070.82 09/02/2025 Non-covered Recipient Entity
STAR VISION RESEARCH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202507067
Principal investigator 1 ABBVIE INC. $18,014.69 08/27/2025 Non-covered Recipient Entity
STAR VISION RESEARCH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506213
Principal investigator 1 Ocular Therapeutix, Inc. $3,232.80 08/22/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239751
Principal investigator 1 ABBVIE INC. $5,000.00 08/21/2025 Non-covered Recipient Entity
STAR VISION RESEARCH PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202505565
Principal investigator 1 Ocular Therapeutix, Inc. $3,622.73 08/20/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,500.00 08/18/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184228655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,268.00 08/18/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184228657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 08/18/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184228659
Principal investigator 1 Ocular Therapeutix, Inc. $5,025.00 08/13/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239747
Principal investigator 1 Ocular Therapeutix, Inc. $14,848.20 08/01/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239743
Principal investigator 1 Ocular Therapeutix, Inc. $49,927.50 08/01/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239745
Principal investigator 1 Ocular Therapeutix, Inc. $3,232.80 07/30/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239741
Principal investigator 1 Ocular Therapeutix, Inc. $8,967.65 07/25/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239739
Principal investigator 1 Ocular Therapeutix, Inc. $1,152.00 07/18/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239735
Principal investigator 1 Ocular Therapeutix, Inc. $1,354.00 07/18/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239737
Principal investigator 1 Ocular Therapeutix, Inc. $3,007.46 07/02/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239731
Principal investigator 1 Ocular Therapeutix, Inc. $3,232.80 07/02/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,500.00 06/26/2025 Non-covered Recipient Entity
STAR VISION CONSULTANTS PLLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184211455
Principal investigator 1 Ocular Therapeutix, Inc. $1,575.00 06/06/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239727
Principal investigator 1 Ocular Therapeutix, Inc. $29,608.00 06/04/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239723
Principal investigator 1 Ocular Therapeutix, Inc. $284.00 06/04/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239725
Principal investigator 1 Ocular Therapeutix, Inc. $21,056.40 05/28/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239721
Principal investigator 1 Ocular Therapeutix, Inc. $2,494.00 05/21/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239717
Principal investigator 1 Ocular Therapeutix, Inc. $3,232.80 05/21/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239719
Principal investigator 1 Ocular Therapeutix, Inc. $1,503.73 05/09/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239713
Principal investigator 1 Ocular Therapeutix, Inc. $47,431.80 05/09/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239715
Principal investigator 1 Ocular Therapeutix, Inc. $3,232.80 04/30/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239711
Principal investigator 1 Ocular Therapeutix, Inc. $2,500.31 04/11/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239709
Principal investigator 1 Ocular Therapeutix, Inc. $429.00 04/02/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239707
Principal investigator 1 Ocular Therapeutix, Inc. $6,465.60 03/26/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239729
Principal investigator 1 Ocular Therapeutix, Inc. $19,612.80 02/05/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239703
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 01/29/2025 Non-covered Recipient Entity
Star Vision Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239705